ANAna Nogal

Ana Nogal

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ana Nogal has a total of 47 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • IL-11 and CCL-1: Novel Protein Diagnostic Biomarkers of Lung Adenocarcinoma in Bronchoalveolar Lavage Fluid (BALF)

    by Maria Delores Pastor, Ana Nogal, Sonia Molina-Pinelo, Álvaro Quintanal-Villalonga, Ricardo Meléndez, I. Ferrer, Beatrice Romero-Romero, Maria José De Miguel, José Luis López-Campos, Jesús Corral, et al.


  • Open Access

    MicroRNA-Dependent Regulation of Transcription in Non-Small Cell Lung Cancer

    by Sonia Molina-Pinelo, Gabriel Gutiérrez, Maria Dolores Pastor, Marta Hergueta, Gema Moreno-Bueno, Rocío García-Carbonero, Ana Nogal, Rocío Suárez, Ana Salinas, Francisco Pozo-Rodríguez, et al.

    Squamous cell lung cancer (SCC) and adenocarcinoma are the most common histological subtypes of non-small cell lung cancer (NSCLC), and have been traditionally managed in the clinic as a single entity. Increasing evidence, however, illustrates the biological diversity of these two histological subgroups of lung cancer, and supports the need to improve our understanding of the molecular basis beyond the different phenotypes if we aim to develop more specific and individualized targeted therapy. The purpose of this study was to identify microRNA (miRNA)-dependent transcriptional regulation differences between SCC and adenocarcinoma histological lung cancer subtypes. In this work, paired miRNA (667 miRNAs by TaqMan Low Density Arrays (TLDA)) and mRNA profiling (Whole Genome 44 K array G112A, Agilent) was performed in tumor samples of 44 NSCLC patients. Nine miRNAs and 56 mRNAs were found to be differentially expressed in SCC versus adenocarcinoma samples. Eleven of these 56 mRNA were predicted as targets of the miRNAs identified to be differently expressed in these two histological conditions. Of them, 6 miRNAs (miR-149, miR-205, miR-375, miR-378, miR-422a and miR-708) and 9 target genes (CEACAM6, CGN, CLDN3, ABCC3, MLPH, ACSL5, TMEM45B, MUC1) were validated by quantitative PCR in an independent cohort of 41 lung cancer patients. Furthermore, the inverse correlation between mRNAs and microRNAs expression was also validated. These results suggest miRNA-dependent transcriptional regulation differences play an important role in determining key hallmarks of NSCLC, and may provide new biomarkers for personalized treatment strategies.


  • Identification of proteomic signatures associated with lung cancer and COPD

    by M D Pastor, A. Nogal, S. Molina-Pinelo, R. Meléndez, A. Salinas, M. González De la Peña, J. Martín-Juan, J. Corral, R. García-Carbonero, A. Carnero, et al.


  • Proteomic biomarkers in lung cancer

    by M. D. Pastor, A. Nogal, S. Molina-Pinelo, A. Carnero, L. Paz-Ares

    The correct understanding of tumour development relies on the comprehensive study of proteins. They are the main orchestrators of vital processes, such as signalling pathways, which drive the carcinogenic process. Proteomic technologies can be applied to cancer research to detect differential protein expression and to assess different responses to treatment. Lung cancer is the number one cause of cancer-related death in the world. Mostly diagnosed at late stages of the disease, lung cancer has one of the lowest 5-year survival rates at 15 %. The use of different proteomic techniques such as two-dimensional gel electrophoresis (2D-PAGE), isotope labelling (ICAT, SILAC, iTRAQ) and mass spectrometry may yield new knowledge on the underlying biology of lung cancer and also allow the development of new early detection tests and the identification of changes in the cancer protein network that are associated with prognosis and drug resistance.


  • Open Access

    Oncoproteomic Approaches in Lung Cancer Research

    by Ma Dolores, Ana Nogal, Sonia Molina-Pinelo, Luis Paz-Ares, Amancio Carnero

    Oncoproteomic Approaches in Lung Cancer Research | IntechOpen, Published on: 2013-03-13. Authors: Ma Dolores Pastor, Ana Nogal, Sonia Molina-Pinelo, et

  • Open Access

    Identification of Oxidative Stress Related Proteins as Biomarkers for Lung Cancer and Chronic Obstructive Pulmonary Disease in Bronchoalveolar Lavage

    by Maria Dolores Pastor, Ana Nogal, Sonia Molina-Pinelo, Ricardo Meléndez, Beatriz Romero-Romero, Maria Dolores Mediano, Jose L. López-Campos, Rocío García-Carbonero, Amparo Sanchez-Gastaldo, Amancio Carnero, et al.

    Lung cancer (LC) and chronic obstructive pulmonary disease (COPD) commonly coexist in smokers, and the presence of COPD increases the risk of developing LC. Cigarette smoke causes oxidative stress and an inflammatory response in lung cells, which in turn may be involved in COPD and lung cancer development. The aim of this study was to identify differential proteomic profiles related to oxidative stress response that were potentially involved in these two pathological entities. Protein content was assessed in the bronchoalveolar lavage (BAL) of 60 patients classified in four groups: COPD, COPD and LC, LC, and control (neither COPD nor LC). Proteins were separated into spots by two dimensional polyacrylamide gel electrophoresis (2D-PAGE) and examined by matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF/TOF). A total of 16 oxidative stress regulatory proteins were differentially expressed in BAL samples from LC and/or COPD patients as compared with the control group. A distinct proteomic reactive oxygen species (ROS) protein signature emerged that characterized lung cancer and COPD. In conclusion, our findings highlight the role of the oxidative stress response proteins in the pathogenic pathways of both diseases, and provide new candidate biomarkers and predictive tools for LC and COPD diagnosis.


  • Quantification of Free Circulating Tumor DNA as a Diagnostic Marker for Breast Cancer

    by Raquel Catarino, Maria M. Ferreira, Helena Rodrigues, Ana Coelho, Ana Nogal, Abreu Sousa, Rui Medeiros

    Aim: To determine whether the amounts of circulating DNA could discriminate between breast cancer patients and healthy individuals by using real-time PCR quantification methodology. Methods: Our standard protocol for quantification of cell-free plasma DNA involved 175 consecutive patients with breast cancer and 80 healthy controls. Results: We found increased levels of circulating DNA in breast cancer patients compared to control individuals (105.2 vs. 77.06 ng/mL, p < 0.001). We also found statistically significant differences in circulating DNA amounts in patients before and after breast surgery (105.2 vs. 59.0 ng/mL, p = 0.001). Increased plasma cell-free DNA concentration was a strong risk factor for breast cancer, conferring an increased risk for the presence of this disease (OR, 12.32; 95% CI, 2.09–52.28; p < 0.001). Conclusions: Quantification of circulating DNA by real-time PCR may be a good and simple tool for detection of breast cancer with a potential to clinical applicability together with other current methods used for monitoring the disease.


  • Open Access

    CXCL12 chemokine genotypes as predictive biomarkers of ovarian cancer outcome

    by Ana Coelho, Deolinda Pereira, Ana Nogal, Daniela Pinto, Raquel Catarino, António Araújo, Rui Medeiros

    Ovarian cancer is an aggressive disease with high mortality. The CXCL12 chemokine has been associated with the development of this neoplasia. The aim of this study was to evaluate the genetic influence of the CXCL12-3'A polymorphism as a prognostic/predictive factor in ovarian cancer patients treated with platinum/paclitaxel chemotherapy. The mean survival rates for early stages (I/II) of the disease were statistically different according to patient genotype (96 months for GG and 57 months for A carrier genotypes; p=0.017). The mean progression-free interval was statistically lower in patients with early stages (I/II) of the tumour carrying the A allele (55 months) than in those carrying the GG genotype (91 months; P=0.009). The CXCL12-3'A polymorphism leads to a poorer response to chemotherapy with cisplatin/paclitaxel, and diminishes the mean survival rate and the progression-free interval in patients with ovarian cancer. CXCL12-3'A may therefore serve as an important predictive biomarker for the determination of outcome in ovarian cancer.


  • The CYP3A4∗1B polymorphism and prostate cancer susceptibility in a Portuguese population

    by Ana Nogal, Ana Coelho, Raquel Catarino, António Morais, Francisco Lobo, Rui Medeiros